FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1362-1369 March 27, 2008 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.

An 18-year-old woman with sickle cell anemia has had increasing symptoms, with painful crises and episodes of the acute chest syndrome. She was hospitalized three times in the past year. A hematologist recommends that hydroxyurea therapy be started.

The Clinical Problem

There . . . [Full Text of this Article]

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Department of Laboratory Medicine, Children's Hospital Boston.

Address reprint requests to Dr. Platt at the Department of Laboratory Medicine, Children's Hospital Boston, 300 Longwood Ave., Boston, MA 02115, or at orah.platt@childrens.harvard.edu.

Related Letters:

Hydroxyurea for Sickle Cell Anemia
Naina H. V.K., Harris S., Bachmeyer C., Aractingi S., Lionnet F., Platt O. S.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:98-99, Jul 3, 2008. Correspondence

This article has been cited by other articles:

• Mueller, B. U. (2008). When Should Hydroxyurea Be Used for Children With Sickle Cell Disease?. Pediatrics 122: 1365-1366 [Full Text]  
• Schechter, A. N. (2008). Hemoglobin research and the origins of molecular medicine. Blood 112: 3927-3938 [Abstract] [Full Text]  
• Lettre, G., Sankaran, V. G., Bezerra, M. A. C., Araujo, A. S., Uda, M., Sanna, S., Cao, A., Schlessinger, D., Costa, F. F., Hirschhorn, J. N., Orkin, S. H. (2008). From the Cover: DNA polymorphisms at the BCL11A, HBS1L-MYB, and {beta}-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl. Acad. Sci. USA 105: 11869-11874 [Abstract] [Full Text]  
• Naina, H. V.K., Harris, S., Bachmeyer, C., Aractingi, S., Lionnet, F., Platt, O. S. (2008). Hydroxyurea for Sickle Cell Anemia. NEJM 359: 98-99 [Full Text]